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Abstract 
 
Involvement of chronic inhibition of monoamine transporters (MAT) in the brain 
concerning the sensitization of cocaine- and local anesthetic-induced seizures was studied in 
mice. Repeated administration of subconvulsive doses of meprylcaine as well as cocaine, both 
of which inhibit MAT, but not lidocaine, which does not inhibit MAT, increased seizure activity 
and produced sensitization to other local anesthetics. Effects of 5 daily treatments of 
monoamine transporter inhibitors on lidocaine-induced convulsions were examined 2 or 3 days 
after the last dose of the inhibitors. The daily treatments of GBR 12935, a specific inhibitor of 
dopamine uptake, significantly increased the incidence and the intensity of lidocaine-induced 
convulsions at 20 mg/kg and decreased the threshold of the convulsions. The daily treatments of 
desipramine and maprotiline, selective norepinephrine uptake inhibitors, markedly increased the 
incidence and intensity of lidocaine-induced convulsions, and decreased the threshold with 
dose-dependent manner between 5 and 20 mg/kg. The daily treatments of citaloplam, a selective 
serotonin uptake inhibitor, 10 and 20 mg/kg, produced no significant increase in the incidence 
or intensity of lidocaine-induced convulsions but decreased the threshold of the convulsions. 
These results suggest that the chronic intermittent inhibition of monoamine uptake increases 
susceptibility to cocaine- and local anesthetic-induced seizures, and a norepinephrine transporter 
is an integral component of this sensitization. 
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1. Introduction 
 
A seizure is a well-known complication of synthetic local anesthetics and of cocaine abuse. 
Local anesthetics activate a limbic discharge, which is most pronounced in the amygdaloid 
nuclear complex [43, 45, 46], though local anesthetics primarily block the Na+ channel, thereby 
inhibiting nerve conductance. It is believed that local anesthetics induce a seizure by depressing 
GABAergic and other inhibitory neurons, thereby allowing the potentiation of excitatory 
neuronal activity [4, 5, 10, 11, 44].  
The repeated administration of cocaine increases its central stimulating activity, displayed 
as an increase in locomotor activity [28]. It has also been demonstrated that intermittent 
repeated administration of relatively high doses of cocaine to rodents increase cocaine-induced 
seizures, called “cocaine kindling” [5, 28]. Cocaine has two prominent pharmacological actions, 
a local anesthetic action and an inhibition of the monoamine transporter (MAT) that, in turn, 
blocks the reuptake of monoamines released from the nerve endings. The latter action, 
especially the blockade of catecholamine reuptake, is closely related to the increase in 
locomotor activity caused by repeated cocaine administration [28]. However, it is not evident 
that the blockade of monoamine reuptake accounts for seizure kindling, because the dose 
required for cocaine kindling is higher than that required to induce locomotor sensitization [47], 
and that development of cocaine-kindled seizures is attenuated by chronic treatment with 
anticonvulsant carbamazepine, though carbamazepine has little effect on locomotor sensitization 
to cocaine [47].  
It has been generally believed that synthetic local anesthetics do not inhibit MAT. However, 
we and others have recently demonstrated that some synthetic local anesthetics such as procaine 
and meprylcaine do inhibit MAT in rat brain synaptosomes [50], in COS cells transfected with 
MAT cDNAs [35] and in SH-SY5Y human neuroblastoma cells [19], while lidocaine displays 
no inhibitory action [35, 48]. Shimosato et al. [41] demonstrated that the repeated 
administration of cocaine sensitizes to lidocaine-induced convulsions, but chronic treatment of 
lidocaine did not affect the cocaine-induced convulsions. In light of our previous observation 
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that a daily treatment for 2 days with nomifensine, which has an inhibitory effect on 
norepinephrine and dopamine uptake, increased the incidence of lidocaine-induced convulsions 
[36], we hypothesized that the inhibition of MAT results in a greater susceptibility to local 
anesthetic-induced convulsions.  
In the present study, the following experiments were performed to elucidate the role of 
chronic inhibition of MAT in the development of drug-induced seizure kindling, 1) whether the 
repeated administration of local anesthetics other than cocaine inhibit MAT increase seizure 
activity, 2) whether the chronic administration of uptake inhibitors for noreinephrine, dopamine 
or serotonin, which may substitute some pharmacological properties of cocaine, produce a 
susceptibility to seizures induced by lidocaine, a typical local anesthetic that does not inhibit 
MAT. 
 
2. Materials and methods 
 
2.1. Animals 
 
Male ICR mice 6 ~ 7 weeks of age (25 ~ 35 g) were used. All procedures and handling of 
the animals were performed according to the guideline by “Guiding Principles for the Care and 
Use of Laboratory Animals” approved by The Japanese Pharmacological Society as well as the 
guideline of Hiroshima University.  
 
2.2. Treatments with drugs  
 
Different subconvulsive dose of cocaine (30, 35, 40 mg/kg) and meprylcaine (80, 85 
mg/kg) and minimal convulsive doses of lidocaine (45, 45 mg/kg) were injected 
intraperitoneally once daily for 4 days. On the 5 th day, lidocaine (50 mg/kg, i.p.) and cocaine 
(40 mg/kg, i.p.) were challenged in cocaine (35, 40 mg/kg) and in meprylcaine (80, 85 mg/kg) 
treated mice, respectively. Monoamine uptake inhibitors, GBR 12935 (i.p.), desipramine (i.p.), 
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maprotiline (i.p.) and citalopram (i.p.), were injected once daily for 5 days. For the timing of 
the drug challenge after the chronic treatment of monoamine uptake inhibitors, Sacchetti et al. 
[34] have reported that the administration of 10 mg/kg i.p. desipramine once daily for 14 days 
significantly raised the basal extracellular norepinephrine in the dorsal hippocampus at 24 hrs 
but not 48 hrs after the last drug injection, and the increase in extracellular norepinephrine by 
the challenge dose of desipramine in rats treated chronically with desipramine was observed in 
rats 48 hrs but not 24 hrs after the last injection. From these results, the authors discussed that 
residual brain concentrations of desipramine were presumably high enough to markedly block 
the norepinephrine uptake at 24 hrs, but not 48 hrs, after the last dose of the chronic 
desipramine [34]. To avoid the possibility of the influence of the residual drugs of the last dose 
of monoamine uptake inhibitors, lidocaine was challenged 2 days and 3 days after the last dose 
to seek the effect on the incidence and the intensity of lidocaine-induced convulsions and the 
threshold of the convulsions, respectively. In some experiments, lidocaine was challenged 5 
and 9 days after the last injection of desipramine. 
 
2.3. Seizures 
 
Mice were intraperitoneally injected with convulsants and placed individually in plastic 
cages for observation of seizure activity. The seizures induced by the drugs were characterized 
by ataxia, a short loss of the righting reflex, and clonic and tonic convulsions. The percentage of 
animals that exhibited convulsions in each treatment group was determined 15 min after the 
injection of the convulsants. The convulsions were scored as, 1= weak, intermittent clonic 
convulsion; 2= typical clonic convulsion lasting more than 1 min; 3= clonic and tonic 
convulsion with increased locomotor activity or jumping. To determine the threshold for 
lidocaine-induced convulsions, the occurrence of clonic convulsion was measured by infusing 
lidocaine solution (4.0 mg/ml) into a tail vein at a rate of 0.21 ml/min via a 24 gauge butterfly 
needle attached to a syringe pump, while the dosage administered was calculated per body 
weight. Other experimental procedures were described previously [36].  
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2.4. Statistical analysis 
 
One-side Fisher’s exact probability test was applied for the frequency of the seizures. 
Student’s t test and Welch test were used to calculate the differences in seizure severity and 
seizure threshold, respectively.  
 
3. Results 
 
3.1. Effects of repeated treatment with cocaine, meprylcaine and lidocaine on local 
anethetic-induced seizures. 
 
    Meprylcaine, which has a relatively potent inhibitory action on MAT, was compared to 
cocaine which is a potent inhibitor of MAT and lidocaine which lacks this property in terms of 
convulsive activity during chronic treatment. Treatment once daily with subconvulsive doses of 
cocaine, 30 ~ 40 mg/kg, for 4 days produced convulsions from the 2 nd day, and the incidence 
of convulsions markedly increased dose- and time-dependently. At 40 mg/kg, all mice 
developed convulsions on the 3 rd and 4 th day. In mice treated once daily with subconvulsive 
doses of meprylcaine, 80 and 85 mg/kg, convulsions appeared from the 2 nd day and % 
incidence of convulsions on the 4 th day reached to 50 and 70, respectively. Lidocaine daily 
treatment for 4 days at even minimal convulsive doses did not affect the convulsive activity 
during the period of the treatment (Fig. 1). In cocaine-treated mice on the 5 th day, lidocaine at a 
dose of 50 mg/kg in which the incidence was 20 % in control mice produced convulsions in all 
animals. In meprylcaine-treated mice on the 5 th day, cocaine with a subconvulsive dose in 
normal mice produced convulsions. These results shows that meprylcaine as well as cocaine but 
not lidocaine produced sensitization to its own convulsive activity and a cross sensitization to 
other local anesthetics although the sensitizing effect of meprylcaine was less potent than 
cocaine. 
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3.2. Effects of repeated administration with inhibitors of monoamine transporters on 
lidocaine-induced seizures. 
  
Cocaine and meprylcaine have a selective inhibitory action on MAT but inhibit all of the 
uptake of dopamine, norepinephrine and serotonin. Effects of a chronic administration of more 
selective inhibitors of dopamine uptake, GBR 12935, of norepinephrine uptake, desipramine 
and maplotiline, and of serotonin, citalopram, on lidocaine-induced convulsions were 
examined under various conditions to clarify whether either the inhibition of dopamine, 
norepinephrine or serotonin uptake produce a susceptibility to convulsions.  
 2 days after the last injection of the daily treatment with GBR 12935, 20 mg/kg once daily for 
5 days, the incidence of lidocaine-induced convulsions and the intensity of symptoms of convulsions 
as shown in convulsion score significantly increased (Table 1). Threshold of lidocaine-induced 
convulsions tested at 3 days after the last injection of GBR 12935, 20 mg/kg, significantly decreased 
(Table 2). In mice treated daily for 5 days with desipramine, the incidence of lidocaine-induced 
convulsions markedly increased 2 days after the last dose of desipramine, and the effect of 
desipramine was dose-dependent between 5 and 20 mg/kg (Table 1). The sensitization produced 
by daily dose of 20 mg/kg lasted until the 5 th day after the last dose of desipramine, with a 
gradual decline. Daily treatment of maprotiline with the similar dosage for 5 days also 
significantly increased the incidence of lidocaine-induced convulsions. Daily treatment with 
desipramine, 10 and 20 mg/kg and maprotiline, 10 and 20 mg/kg remarkably intensified the 
intensity of convulsions induced by lidocaine as shown in an increase of lidocaine’s convulsive 
score (Table 1). 3 days after the last dose of 5 daily treatments of 10 and 20 mg/kg of 
desipramine and maprotiline, the convulsive threshold for lidocaine was profoundly lower 
(Table 2).  
In the present study, we observed that acute treatment with citalopram, which is an SSRI 
without action on cytochrome P-450 and thereby considered to avoid the influence on lidocaine 
metabolism, significantly increased the incidence of lidocaine-induced convulsions; % 
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incidence of convulsions induced by lidocaine (40 mg/kg) in the control and citalopram (10 
mg/kg of citalopram was injected 30 min before the injection of lidocaine)-treated group were 
9.4 and 66.7, respectively (p<0.05). Therefore, we next examined the chronic effect of 
citalopram on seizure activity related to lidocaine. The 5 daily treatments of citalopram, 20 
mg/kg but not 10 mg/kg produced slight, but not significant increase in the incidence of 
convulsions induced by lidocaine, and did not change the seizure score of lidocaine (Table 1). 
Seizure threshold of lidocaine was significantly reduced by citalopram at 10 and 20 mg/kg but 
to a lesser degree than with desipramine and maprotiline (Table 2). 
 
4. Discussion 
 
  Cocaine is known to inhibit MAT including dopamine transporter (DAT), norepinephrine 
transporter (NET) and serotonin transporter (SERT). The mood-enhancing and psychomotor 
stimulation effects of cocaine are thought to be related primarily to the inhibition of MAT, 
especially DAT [32]. While synthetic local anesthetics are generally believed to lack this effect, 
certain local anesthetics such as procaine have cocaine-like reinforcing effects in animals [7, 18, 
29, 49, 50]. Recently, it has been demonstrated that certain local anesthetics including procaine 
do inhibit MAT [19, 35, 48], and this effect, especially inhibition of DAT, would explain their 
cocaine-like effect [5, 48].  Among local anesthetics tested in our former study, meprylcaine 
had relatively potent inhibitory action on MAT although less potent than cocaine, while 
lidocaine had not [35]. Thus the effect of a repeated administration of cocaine, meprylcaine and 
lidocaine in the development of seizures were compared to elucidate the relation of the 
inhibition of MAT in the development of kindling. It has been reported that sensitization to 
cocaine-induced convulsions by a daily treatment with a minimal convulsive dose of cocaine 
reached a peak response after 4 to 5 days and by a daily treatment with a sub-convulsive dose of 
cocaine appeared on the 5 th day, and the treatment for a longer period produced tolerance [23], 
although the sensitivity to cocaine kindling differ with strain of mice [21]. In consistent with 
these results, daily treatments of subconvulsive doses of cocaine produced the susceptibility to 
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lidocaine-induced convulsions during 4 days treatment with dose- and time-dependent manner 
in the present study. Daily treatments of meprylcaine also increased the susceptibility to 
convulsions with less potency than cocaine in relate with their potency of MAT inhibition [35]. 
In cocaine- and meprylcaine-treated mice, a cross sensitization to other local anesthetics was 
displayed, although a repeated administration of lidocaine did not produce the sensitization of 
convulsions. These results showed that the chronic administration of local anesthetics, cocaine 
and meprylcaine, which inhibit monoamine uptake, can facilitate convulsive activity but 
lidocaine, which lacks this property, did not.  Thus, the local anesthetic action alone was either 
unrelated or insufficient to develop seizure kindling, although lidocaine has been reported to 
induce seizure kindling by repeated administration for longer periods than used here [27]. 
Therefore, it is suggested that the chronic inhibition of MAT is closely related with development 
of local anesthetic-induced kindling. 
It has been shown that cocaine and meprylcaine inhibit the uptake of norepinephrine, 
dopamine and serotonin with almost equal potency [35]. The administration of cocaine and 
meprylcaine could inhibit the uptake of these amines in vivo. We have previously observed that 
injection for 2 days of nomifensine, which inhibits both norepinephrine and dopamine, 
facilitated lidocaine-induced convulsions [36]. Daily administration of more selective inhibitors 
of norepinephrine uptake, desipramine, but not selective inhibitor of dopamine, GBR 12935, for 
2 days actually potentiated lidocaine-induced convulsions 1 day after the last injection of 
monoamine uptake inhibitors (data not shown). However, it has been reported that the residual 
brain concentrations of desipramine could block norepinephrine uptake at 24 hrs, but not 48 hrs, 
after the last dose of the chronic desipramine (10 mg/kg i.p. desipramine once daily for 14 days) 
[34]. To avoid the possible influence of the residual drugs of the last dose of monoamine uptake 
inhibitors, lidocaine was challenged at 2 days and 3 days after the last dose of monoamine 
uptake inhibitors to seek their effects on the incidence and severity of lidocaine-convulsion and 
threshold of the convulsions, respectively. Desipramine and maplotiline at 5 ~ 20 mg/kg 
dose-dependently produced a remarkable increase in the incidence of lidocaine-induced 
convulsions, lidocaine’s convulsive score, and reduction in the convulsive threshold for 
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lidocaine. The sensitization by desipramine to lidocaine convulsions lasted for 5 days after 
withdrawal of the inhibitors. It has been reported that extracellular norepinephrine concentration 
was increased in locus coeruleus and cingulated cortex following the acute administration of 
desipramine as low as 3 mg/kg, i.p. in rats [22]. It could be assumed that the reuptake of 
norepinephrine is effectively blocked by the systemic administration of these doses of 
norepinephrine uptake inhibitors used in the present study. Thus, repeated previous inhibition of 
norepinephrine uptake produced plastic changes that lead to increased susceptibility to local 
anesthetic-induced convulsions. Previously, Jackson et al. [17] reported that acute treatments 
with a norepinephrine uptake inhibitor and α2 adrenoceptor–antagonists, both of which increase 
noradrenergic synaptic activity, neither increased nor decreased cocaine-induced convulsions, 
concluding that no noradrenergic mechanism is involved in the cocaine-induced convulsion. 
However, Russell and Stripling [33] showed that cocaine’s noradrenargic action modulated a 
kindling expression via a daily electrical stimulation of the left prepyriform cortex. Further, we 
observed that concurrent, acute pharmacological manipulations to stimulate the central 
noradrenergic nervous system enhanced the convulsions induced by lidocaine, while those for 
inhibition decreased the convulsions [5, 51]. Therefore, the present study indicates that 
previously increased noradrenergic activity results in potentiation of convulsive activity of local 
anesthetics. 
Although the lack of acute effects of a dopamine uptake inhibitor on lidocaine-induced 
convulsions do not support the involvement of dopaminergic functions in local anesthetic 
convulsions [36], Ciarlone [3] reported that depletion of brain dopamine without changing the 
norepinephrine levels decreased the convulsant thresholds for lidocaine and procaine. In the 
present study, a daily treatment with GBR 12935 at 20 mg/kg for 5 days increased the incidence 
of lidocaine convulsions and intensified the symptoms of convulsions as shown in an increase 
of score and decreased the threshold, although the effects of GBR 12935 were less potent than 
desipramine and maprotiline. It has been reported that GBR 12935 at 15 mg/kg produced not 
only an increase in dopamine level in dialysate of nucleus accumbens but profound increase in 
norepinephrine level in ventral tegmental erea in rats [29], suggesting the cross talk between 
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monoaminergic systems occurring upon systemic administration of the uptake inhibitor. 
Therefore, the sensitization to lidocaine convulsions by chronic GBR 12935 at a high dose of 20 
mg/kg may be due to either the activation of dopaminergic neronal system or via the indirect 
interaction with noradrenergic nervous system.  
It has been suggested that cocaine-induced convulsions are modified by an acute 
manipulation of serotonergic activity rather than noradrenergic and dopaminergic activity. For 
example, a cocaine-induced seizure is markedly enhanced by acute treatment with the selective 
serotonin reuptake inhibitors (SSRI) [24, 30, 31], while the 5-HT2 receptor antagonists 
antagonize cocaine seizure [25, 31, 37]. Thus, the SERT is thought to be a primary site of action 
mediating the modification of seizures induced by acute injections of cocaine. Intraperitoneal 
administration of citalopram, a potent and selective inhibitor of serotonin uptake has shown to 
increase significantly dialysate serotonin in the dorsal raphe of rats at 1 mg/kg, a greater effect 
at 10 mg/kg [12]. In the present study, we observed that acute treatment with 10 mg/kg of 
citalopram actually increased the incidence of lidocaine-induced convulsions. However, the 
chronic treatment with citaloplam, 10 mg/kg and even higher dosage of 20 mg/kg had no effect 
on the incidence or severity of symptoms of lidocaine-induced convulsions with a slight 
decrease in threshold. Thus, chronic inhibition of SERT may play a minor role in the facilitation 
of a seizure induced by local anesthetics, though acute inhibition plays an important role. 
The direct blockade of monoamine uptake can account for the elevation of extracellular 
level of monoamine neurotransmitters, which would alter the pre- and post-synaptic neuronal 
functions. For examples, down-regulation of α2-adrenoceptor-mediated responses in the CNS 
are common responses observed to the chronic treatment with antidepressant drugs that increase 
synaptic norepinephrine concentration [2, 8, 9]. Although the obvious changes of MAT would 
be expected with the blockade of monoamine uptake, there have been mixed results regarding 
MAT regulation following a chronic exposure to cocaine and antidepressants [52]. Experimental 
differences in the dose and period of drug administration, drug withdrawal times, brain regions 
studied, etc., may contribute to the variable results [52]. Behavioral studies in rodents showed 
that motor stimulant effects of dopamine agonists were potentiated by the repeated, but not 
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acute, administration of various antidepressant or by repeated convulsive shock, accompanied 
with concomitant activation of dopamine D2-like receptors [1, 42]. Several studies of 
postsynaptic mechanism have indicated that an excitatory amino acid transmission is involved 
in cocaine seizure kindling. Increased susceptibility to a cocaine-induced seizure is associated 
with the up-regulation of cortical NMDA receptors [16], with a marked increase in NMDA 
receptor density in the sriatum, amygdala and hippocampus and an increase in the affinity of 
NMDA receptors in the hippocampus [15]. Moreover, cocaine kindling is blocked by 
co-administration with an antagonist of N-methyl-D-aspartate (NMDA) glutamate receptors, 
dizocilpine (MK-801) [16, 20, 38]. Pretreatment with nitric oxide synthase (NOS) inhibitors 
prior to cocaine administration abolished the cocaine-induced up-regulation of NMDA receptors 
and the induction and expression of cocaine kindling without affecting the acute 
cocaine-seizures [13, 14, 26]. These findings suggest that iNOS induction followed by an 
increase in the NMDA receptor function after repeated exposure to cocaine is associated with 
fundamental cellular processes required for the cascade leading to cocaine sensitization. 
Shimosato et al reported an increase in polyamine levels associated with changes in the 
sensitivity to convulsions during chronic treatment with cocaine, and that the 
intracerebroventricular administration of spermidine enhanced seizures induced by cocaine, 
lidocaine and NMDA [39, 40]. Spermidine may play an important role in the development of 
susceptibility to seizure activity by cocaine via the modulation of NMDA receptors.  
Further study is required concerning the mechanism of the development of the 
susceptibility to a local anesthetic-induced seizure by the chronic administration of MAT 
inhibitors; e.g., whether the chronic inhibition of MAT alters such pre-synaptic receptor 
functions, transporter functions and/or postsynaptic functions as the molecular changes in the 
NO/NMDA signaling pathway. 
In conclusion, the present results suggest that intermittent chronic inhibition of MAT, 
especially NET in the brain, induces plastic changes that facilitate seizure activity induced by 
local anesthetics. Such changes may be involved in cocaine kindling. 
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Figure legend. 
 
Fig.1 Effects of daily treatment with cocaine (A), meprylcaine (B) and lidocaine (C) on seizure 
activity in mice. Drugs were injected intraperitoneally once a day. After 4 days of treatment with 
cocaine (A) or meprylcaine (B), lidocaine 50 mg/kg, a minimal convulsive dose on day 1 as 
shown in (C), or cocaine 40 mg/kg, a subconvulsive dose on day 1 as shown in (A), were 
administered to mice treated with cocaine (A) or meprylcaine (B), respectively. Number of 
animals used were 15-20 mice each group. 
 
 
Table 1  
Effects of chronic treatment with specific inhibitors of dopamine-, norepinephrine- and 
serotonin-transporter on seizure activity induced by lidocaine in mice.  
    
Lidocaine (40 mg/kg i.p.)  
Pretreatment 
(mg/kg i.p.) 
Term 
of 
pretreatment 
(days) 
Term 
of 
rest 
(days)
% incidence N1 Score a) 
 
N2
Saline 5 2 12.0 50 1.2 ± 0.2 6
GBR12935    (5) 5 2 20.0 25 2.0 ± 0.4 5
 (20) 5 2 45.0** 20 1.7 ± 0.2† 9
     
Saline 5 2 7.2 83 1.2 ± 0.2 6
Saline 5 5 6.7 15 1.0 1
Saline 5 9 6.7 15 1.0 1
Desipramine   (2) 5 2 6.7 15 2.0 1
 (5) 5 2 40.0** 15 1.5 ± 0.2 6
 (10) 5 2 73.3** 15 1.9 ± 0.2† 11
 (20) 5 2 88.6** 35 2.4 ± 0.1†† 31
 (20) 5 5 40.0* 15 2.5 ± 0.4 6
 (20) 5 9 26.7 15 1.5 ± 0.3 4
     
Saline 5 2 10.3 68 1.1 ± 0.1 7
Maprotiline   (2) 5 2 13.3 15 2.0 ± 1.4 2
(5) 5 2 40.0* 15 2.2 ± 0.3†† 6
(10) 5 2 52.0** 25 2.2 ± 0.2†† 10
 (20) 5 2 65.0** 20 2.2 ± 0.2†† 13
     
Saline 5 2 9.4 53 1.2 ± 0.2 5
Citalopram   (10) 5 2 3.3 30 1.0 1
(20) 5 2 20.0 30 1.2 ± 0.2 6
GBR12935, desipramine, maprotiline, citalopram, or an equal volume of saline were injected once 
every day at the indicated dose for 5 days, and then 2, 5 or 9 days after the last injection the mice 
were challenged with lidocaine. 
a) Seizure score is seizure severity quantified according to the following rating scale: 1= weak, 
intermittent clonic convulsion, 2= typical clonic convulsion lasting more than 1 min, 3= clonic and 
tonic convulsion with increased locomotor activity or jumping. These scores were counted for each 
seizure-generalized mouse. Data are expressed as mean ± S.E.M. of the seizure score in mice. 
One-side Fisher’s exact probability test was used for seizure susceptibility; *p<0.05; **p<0.01 vs. saline. 
Student’t t test was used to calculate differences in seizure severity; †p<0.05; ††p<0.01 vs. saline.  
N1; number of mice used.  N2; number of mice with convulsions. 
 
  
 
 
Table 2  
Effects of chronic treatment with specific inhibitors of dopamine-, norepinephrine- and 
serotonin- transporter on seizure threshold for lidocaine in mice.  
   
Lidocaine convulsive threshold Pretreatment  
(mg/kg i.p.) 
Term of 
pretreatment 
(days) 
Term of 
rest 
(days) (mg/kg i.v.) N 
Saline 5 3 24.7 ± 0.1 10 
GBR12935   (20) 5 3 22.3 ± 0.7* 10 
     
Saline 5 3 24.8 ± 0.2 40 
Desipramine   (2) 5 3 24.1 ± 0.5 10 
 (5) 5 3 21.4 ± 0.9* 8 
(10) 5 3 18.8 ± 0.6** 8 
(20) 5 3 14.9 ± 0.6** 13 
     
Saline 5 3 25.1 ± 0.5 23 
Maprotiline    (2) 5 3 23.7 ± 0.6 10 
(5) 5 3 19.3 ± 0.4** 10 
(10) 5 3 15.9 ± 0.5** 10 
 (20) 5 3 14.3 ± 0.9** 8 
     
Saline 5 3 24.8 ± 0.2 40 
Citalopram    (10) 5 3 21.0 ± 0.5** 35 
(20) 5 3 22.3 ± 0.5** 20 
Drugs were injected once every day at the indicated dose and days. Three days after the last injection 
the mice were challenged with lidocaine. Lidocaine (4.0 mg/ml) was infused into a tail vain at a rate 
of 0.21 ml/min until the onset of seizure. Data are expressed as mean ± S.E.M. of the threshold for 
lidocaine-induced seizure activity in mice. The Welch test was used for seizure threshold; *p<0.01; 
**p<0.001 vs. saline.  N; number of mice used. 
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